Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 12/20 | 0.42 |
| ▸ | RAB9A | P51151 | 12/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19270384 | 0.84 | RAB9A (0.47) | ABL1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL19253772 | 0.82 | ABL1 (0.41) | ABL1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL19253710 | 0.81 | RAB9A (0.47) | ABL1DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19253659 | 0.81 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL19253774 | 0.81 | LRRK2 (0.61) | ABL1DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19253641 | 0.80 | NPC1 (0.48) | ABL1DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19253643 | 0.80 | ABL1 (0.43) | ABL1DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19270380 | 0.80 | ABL1 (0.41) | ABL1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL19253738 | 0.80 | MEN1 (0.45) | ABL1DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19253695 | 0.80 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180235943-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-08-23 | — | — | US | disclosed |
| US-9895358-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895358-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2017147312-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-08-24 | — | — | US | disclosed |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235943-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYOF | ABL1 2209/4885CSNK2A2 321/4885CSNK2B 303/4885 |
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | SMN1; SMN2, MUSK, MYOF | ABL1 2209/4885CSNK2A2 321/4885CSNK2B 303/4885 |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYOF | ABL1 2209/4885CSNK2A2 321/4885CSNK2B 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.